ChromaDex Corporation

7.96-0.2400-2.93%Vol 1.57M1Y Perf 114.17%
Apr 19th, 2021 16:00 DELAYED
BID7.92 ASK8.04
Open8.14 Previous Close8.20
Pre-Market- After-Market7.92
 - -  -0.04 -0.50%
Target Price
15.75 
Analyst Rating
Strong Buy 1.00
Potential %
97.86 
Finscreener Ranking
★★★★     54.06
Insiders Trans % 3/6/12 mo.
-100/-50/-20 
Value Ranking
★+     45.27
Insiders Value % 3/6/12 mo.
-100/-95/-94 
Growth Ranking
★★+     50.83
Insiders Shares Cnt. % 3/6/12 mo.
-100/-90/-88 
Income Ranking
 —    -
Market Cap531.39M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
20.87 
Earnings Date
10th May 2021

Today's Price Range

7.948.39

52W Range

3.8223.66

5 Year PE Ratio Range

-27.50-8.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-11.95%
1 Month
-33.11%
3 Months
66.88%
6 Months
61.13%
1 Year
114.17%
3 Years
91.81%
5 Years
83.83%
10 Years
57.94%

TickerPriceChg.Chg.%
CDXC7.96-0.2400-2.93
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
1.20
2.00
0.06
0.10
-279.60
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
59.50
-33.50
-31.00
-59.50
-30.87
RevenueValueIndustryS&P 500US Markets
44.91M
0.67
33.83
20.20
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.11-0.109.09
Q03 2020-0.11-0.0736.36
Q02 2020-0.11-0.0645.45
Q01 2020-0.11-0.0918.18
Q04 2019-0.12-0.118.33
Q03 2019-0.15-0.1126.67
Q02 2019-0.16-0.1412.50
Q01 2019-0.15-0.150.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0910.00Positive
6/2021 QR-0.080.00-
12/2021 FY-0.30-42.86Negative
12/2022 FY-0.03-116.67Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.09
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.57M
Shares Outstanding66.76M
Trades Count5.84K
Dollar Volume2.11B
Avg. Volume3.30M
Avg. Weekly Volume737.23K
Avg. Monthly Volume1.12M
Avg. Quarterly Volume3.83M

ChromaDex Corporation (NASDAQ: CDXC) stock closed at 7.96 per share at the end of the most recent trading day (a -2.93% change compared to the prior day closing price) with a volume of 1.57M shares and market capitalization of 531.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. ChromaDex Corporation CEO is Robert N. Fried.

The one-year performance of ChromaDex Corporation stock is 114.17%, while year-to-date (YTD) performance is 65.83%. CDXC stock has a five-year performance of 83.83%. Its 52-week range is between 3.82 and 23.66, which gives CDXC stock a 52-week price range ratio of 20.87%

ChromaDex Corporation currently has a PE ratio of -24.80, a price-to-book (PB) ratio of 33.33, a price-to-sale (PS) ratio of 11.83, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.49%, a ROC of -89.90% and a ROE of -103.02%. The company’s profit margin is -30.87%, its EBITDA margin is -31.00%, and its revenue ttm is $44.91 Million , which makes it $0.67 revenue per share.

Of the last four earnings reports from ChromaDex Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. ChromaDex Corporation’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for ChromaDex Corporation is Strong Buy (1), with a target price of $15.75, which is +97.86% compared to the current price. The earnings rating for ChromaDex Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ChromaDex Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ChromaDex Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 46.67, ATR14 : 1.56, CCI20 : -145.57, Chaikin Money Flow : -0.41, MACD : 0.31, Money Flow Index : 48.91, ROC : -14.78, RSI : 51.24, STOCH (14,3) : 0.61, STOCH RSI : 0.00, UO : 27.48, Williams %R : -99.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ChromaDex Corporation in the last 12-months were: Frank L. Jaksch (Option Excercise at a value of $192 502), Frank L. Jaksch (Sold 37 829 shares of value $196 333 ), Kevin M. Farr (Buy at a value of $22 150), Robert N. Fried (Buy at a value of $4 690), Stephen A. Block (Option Excercise at a value of $114 500), Stephen A. Block (Sold 52 500 shares of value $625 775 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ChromaDex Corporation

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

CEO: Robert N. Fried

Telephone: +949.419.0288 ext. 127

Address: 10900 Wilshire Boulevard, Los Angeles 90024, CA, US

Number of employees: 110

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

56%44%

Bearish Bullish

56%44%

News

Stocktwits